Prognostic factors in 42 patients aged 11 to 62 (median 46) years, with myelodysplastic syndrome (MDS) or after leukemic transformation, who underwent allogeneic marrow transplantation between 1984 and 1999 were analyzed. Thirty-six had advanced disease morphology; 19 had leukemic transformation. Twenty-nine received a preparative regimen of BuCy 2 and 13 busulfan 14 mg/kg, etoposide 50 mg/kg and cyclophosphamide 120 mg/kg. Severe hepatic veno-occlusive disease (VOD) occurred in three patients all of whom received anti-leukemic chemotherapy prior to transplantation. Fifteen patients (36%) died from early transplantrelated complications; nine patients relapsed. The estimated 4 year disease-free survival (DFS) was 35% (95% CI 26-44%). Older age was the most significant adverse prognostic factor. Patients with leukemic transformation who underwent early transplantation had significantly better DFS than those treated first with chemotherapy (P = 0.002). Delayed toxicity was rare in these patients; no late relapses occurred. Bone Marrow Transplantation (2000) 25, 1219-1222. Keywords: myelodysplastic syndrome; BuCy; allogeneic transplantation Allogeneic marrow transplantation is the only curative treatment for the myelodysplastic syndrome (MDS).
to cyclophosphamide and total body irradiation (TBI), have resulted in lower relapse rates, but also an increase in nonrelapse mortality. 6 Regimens using busulfan without total body irradiation have yielded favorable results for patients with MDS. 5, 7 The present study analyzed long-term results and prognostic factors in patients with MDS, most with advanced disease, who received busulfan-based preparative therapy.
Subjects and methods

Patients
Between March 1984 and May 1999, 42 consecutive patients with histologically confirmed MDS and age of less than or equal to 65 years underwent a first allogeneic marrow transplantation from an HLA-identical or one antigen mismatched related or unrelated donor. Protocols were reviewed and approved by the Institutional Review Board. All patients signed informed consent forms. Analysis was based on data available as of 15 August 1999.
Preparative regimens
Patients received busulfan at 16 mg/kg in divided doses of 1 mg/kg every 6 h for 4 consecutive days (days −7 to −4). Cyclophosphamide was then administered intravenously at 60 mg/kg on days −3 and day −2. Thirteen consecutive patients transplanted between June 1994 and April 1998 received busulfan 1 mg/kg for 14 consecutive doses, followed by etoposide 50 mg/kg administered intravenously by continuous infusion over 36 h, and cyclophosphamide 60 mg/kg intravenously on days −3 and −2. All patients received phenytoin prophylaxis prior to and during busulfan administration.
Supportive care
All patients were cared for in private rooms with modified protective isolation and received prophylactic oral gut decontamination with antimicrobial agents prior to and during neutropenic intervals. Bone marrow examination was performed in all patients within 1 week of beginning preparative therapy and was repeated 1 month after transplant.
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Hematopoietic recovery
Engraftment was judged to have occurred on the first of 3 consecutive days that the neutrophil count exceeded 0.5 × 10 9 /l. Platelet recovery was defined as a platelet count exceeding 20 × 10 9 /l without a platelet transfusion.
Complications
Acute 8 and chronic graft-versus-host disease (GVHD), 9 hepatic veno-occlusive disease (VOD) 10 and obstructive bronchiolitis 11 were defined and graded according to previously published criteria.
Statistical methods
Univariate analyses of relapse, survival, and event-free survival used the Kaplan-Meier product limit method 12 with logrank tests 13 of survival curves. Cox proportional hazards regression 14 was used in multivariate analyses to identify possible prognostic factors.
Results
Patient characteristics
The median patient age was 46 (range 11-62) years. Twenty-seven patients had primary MDS; 15 had received prior chemotherapy and/or radiation therapy. Twenty patients had cytogenetic abnormalities; 22 patients had normal cytogenetic studies. There were 16 females and 26 males. All six patients who did not have advanced morphology had either intermediate or poor risk karyotype or at least two cytopenias, placing all patients in the intermediate or high risk categories of the IPSS for MDS. Six patients had refractory anemia, eight had RAEB, seven had RAEB-T, two had CMML, and 19 patients had undergone leukemic transformation at the time of transplantation. An additional nine patients with identified HLA-identical sibling donors who had undergone leukemic transformation were treated with chemotherapy prior to intended transplantation, but never underwent a transplant procedure. Thirtyfive patients received marrow from a genotypically matched sibling, four patients from a matched unrelated donor, and three patients from one antigen mismatched family member. For prevention of GVHD, 10 patients transplanted prior to November 1991 received a previously described regimen of cyclosporine tapered over 6 months and methylprednisolone tapered over 10 weeks. 15 Thirty-two patients transplanted after November 1991 received methotrexate and cyclosporine as previously described by Storb et al. 16 
Engraftment
All evaluable patients engrafted. The median time to a neutrophil count of 500 was 19 (range 12-88) days and to a self-sustaining platelet count in excess of 20 000 was 26 (range 14-89) days. 
Regimen-related toxicity
All patients developed grade one or greater oral toxicity. The most common life-threatening toxicity was severe hepatic VOD which occurred in three patients (7%); 18 patients (43%) developed hepatic VOD. Severe VOD occurred exclusively in patients treated with anti-leukemic chemotherapy prior to allogeneic bone marrow transplantation.
GVHD
Eight of 42 patients (19%) developed grade two or greater acute GVHD and 11 of 36 evaluable patients (31%) developed extensive chronic GVHD.
Delayed complications
No secondary malignancies have developed. One patient developed obstructive bronchiolitis; one patient had a Karnofsky score of less than 90 at the time of data analysis due to chronic GVHD. Two men fathered four children following allogeneic bone marrow transplantation; neither had received chemotherapy aside from BuCy 2 .
Disease-free survival
Fifteen of 42 patients (36%) died from transplant-related complications; nine patients relapsed. The estimated relapse rate at 4 years is 46.2% (95% confidence interval (CI) 34.8-47.6%) (Figure 1 ). The causes of death in 22 patients who died are described in Table 1 . Eighteen patients are disease- (Figure 2 ). Multivariate analysis demonstrated that older age was a significant poor prognostic factor (P = 0.01). Longer interval from diagnosis to transplantation (P = 0.16), higher percentage of marrow blasts prior to transplantation (P = 0.19), and treatment with chemotherapy prior to the development of MDS (P = 0.20) were associated, though not significantly, with poorer prognosis. Of the 19 patients with leukemic transformation who underwent transplantation, eight did not receive antileukemic chemotherapy prior to transplant. Five of these eight are disease-free survivors 5-15 years following transplantation. Anti-leukemic chemotherapy consisted of standard doses of cytarabine and an anthracycline in seven patients and of high-dose cytarabine regimens in four patients. Four of 11 patients achieved complete remission with anti-leukemic therapy. Only two of 11 patients who underwent anti-leukemic therapy followed by transplantation are long-term survivors. Both of the patients who are long-term leukemia-free survivors were in complete remission at the time of transplantation. Nine patients who were eligible for transplantation but were first treated with chemotherapy and never came to transplantation died within 8 months of their first chemotherapy treatment. Four of the nine received standard cytarabine and an anthracycline and five patients received high-dose cytarabine. None attained remission. Comparing patients who received chemotherapy to those who did not receive antileukemic therapy prior to transplantation, no significant differences were detected for age, percentage of marrow blasts, interval from diagnosis to treatment, or treatment with chemotherapy before the development of MDS (P Ͼ 0.2). DFS was significantly better for patients who underwent allogeneic bone marrow transplantation as first line treatment for leukemic transformation than for those, including the nine patients who died without allogeneic bone marrow transplantation, first treated with chemotherapy (P = 0.002). 
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Discussion
This present study illustrates the effectiveness of busulfanbased regimens followed by allogeneic bone marrow transplantation as therapy for patients with MDS including those with advanced disease morphology and leukemic transformation. In other trials with busulfan in MDS, patients have had less advanced disease 5, 15, 16 and have been younger. 4, 5, 17, 18 The results of this trial appear to be comparable to those achieved with TBI-containing regimens [2] [3] [4] 6, 7 considering patient age and extent of disease. The heterogeneity of the patient population and the relatively small number of patients studied do not permit firm conclusions as to the relative effectiveness of the preparative regimens utilized in this study. Advantages of busulfan include ease of administration, less expense, greater convenience, and according to some studies, less acute toxicities including a lower incidence of infections and shorter duration of neutropenia. 19 A higher incidence of hepatic VOD occurs than with radiation, 10 however, risk factors for the development of VOD following busulfan have been identified. 10, 20, 21 In the present study, the three patients who developed severe hepatic VOD had all received anti-leukemic chemotherapy prior to transplantation.
We have previously reported on the safety of BuCy 2 even in older patients. 22 We were unable to find a significant prognostic influence of age on outcome in a recent analysis of 164 patients with CML up to age 66 who underwent allogeneic transplantation following BuCy 2 . 23 However, in this study, older age was the most significant adverse prognostic factor.
The present study suggests that patients with leukemic transformation of MDS have a better chance for sustained disease-free survival when brought quickly to transplantation without other anti-leukemic therapy. While the relative effectiveness of BuCy 2 in AML was inferior to Cy/TBI in a randomized study, 24 other studies have supported its effectiveness in AML. 25, 26 The high incidences of chronic GVHD and of obstructive bronchiolitis reported following busulfan in one study 27 were not seen in the present study nor has it been confirmed by other studies. 28 The results of the present trial support the use of busulfan without total body irradiation in patients with MDS with advanced morphology or leukemic transformation, and argue against the use of antileukemic therapy prior to transplantation even in patients who have undergone leukemic transformation.
